Estrogen Protects Mice From Cardiac Hypertrophy Induced by Calcium Dysregulation

NEW YORK (Reuters Health) Mar 20 – In a murine model of cardiac hypertrophy, anti-estrogen treatment abolishes the normally protected status of female animals, researchers show.
Writing in the March 21st issue of Nature, Dr. Michael I. Kotlikoff from Cornell University, Ithaca, New York, and colleagues report on experiments in transgenic mice lacking FK binding protein 12.6 (FKBP12.6).

FKBP12.6 is the receptor site for the immunosuppressant drug FK506, the researchers note. Both male and female FKBP12.6-null mice exhibit disruptions in calcium release from the sarcoplasmic reticulum in skeletal muscle. While this causes males to developed cardiac hypertrophy, female remain normal.

When Dr. Kotlikoff's team treated female mice with the estrogen receptor antagonist, tamoxifen, the female mice developed cardiac hypertrophy similar to the male mice.

לכתבה

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים